Can the predictive value of multiparametric MRI for prostate cancer be improved by a liquid biopsy with SelectMDx?

BACKGROUND: SelectMDx is a urinary biomarker test for determining prostate cancer risk. AIM: In a group of patients with a biopsy proven prostate cancer (PCa) who had undergone a multi parametric Magnetic Resonance Imaging (mpMRI) and urinary biomarker test with SelectMDx, we studied the additive va...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahnama'i, Mohammad Sajjad, Bach, Christian, Schulze‐Hagen, Maximilian, Kuhl, Christiane K, Vögeli, Thomas Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714534/
https://www.ncbi.nlm.nih.gov/pubmed/33931984
http://dx.doi.org/10.1002/cnr2.1396

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714534/
https://www.ncbi.nlm.nih.gov/pubmed/33931984
http://dx.doi.org/10.1002/cnr2.1396

Ejemplares similares